Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Net Margin (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Net Margin for 15 consecutive years, with 14.2% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 1554.0% to 14.2% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 66.12% through Dec 2025, down 5335.0% year-over-year, with the annual reading at 66.15% for FY2025, 5330.0% down from the prior year.
  • Net Margin for Q4 2025 was 14.2% at Harvard Bioscience, down from 5.99% in the prior quarter.
  • The five-year high for Net Margin was 8.34% in Q2 2022, with the low at 231.19% in Q1 2025.
  • Average Net Margin over 5 years is 18.17%, with a median of 5.75% recorded in 2022.
  • The sharpest move saw Net Margin soared 2611bps in 2023, then crashed -21208bps in 2025.
  • Over 5 years, Net Margin stood at 1.78% in 2021, then tumbled by -428bps to 5.86% in 2022, then rose by 4bps to 5.65% in 2023, then soared by 124bps to 1.34% in 2024, then tumbled by -1163bps to 14.2% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 14.2%, 5.99%, and 11.17% for Q4 2025, Q3 2025, and Q2 2025 respectively.